Megakaryocyte: a new player in systemic lupus erythematosus
Dr. Boilard and his team have determined that an SLE-prone environment alters bioenergetic functions and gene expression in bone marrow megakaryocytes (MK). The data obtained from the Lupus Canada Catalyst grant project had significant impact on Dr. Boilard’s team to secure additional funding.
“We have been successful at the CIHR competition and were recently awarded $734,400 CAD to study how MKs and platelets contribute to SLE. We ranked #1st in the competition and we feel the support from Lupus Canada was a real springboard that contributed to our success.” Dr. Boilard.
For more information on Dr. Boilard’s study please visit https://www.lupuscanada.org/2022-recipient-of-the-lupus-canada-catalyst-award/